Skip to main content

Table 3 Preclinical and clinical trials for lung diseases using amniotic membrane cells

From: Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?

Title

Diseases

Cell type

Type of study

Outcome

Cell therapy

Authors

Intratracheal transplantation of amnion-derived mesenchymal stem cells ameliorates hyperoxia-induced neonatal hyperoxic lung injury via aminoacyl-peptide hydrolase.

Neonatal lung injury

CM- hAMSCs

EXO-hAMSCs

hAMSCs

Preclinical

✓ Reducing pulmonary edema and inflammatory cell infiltration

AI effect

Li et al. [1]

Human amnion-derived mesenchymal stem cells alleviate lung injury induced by white smoke inhalation in rats

Lung injury

hAMSCs

Preclinical

✓ Reducing lung injury, lung fibrosis, CT score, and inflammation levels

AI and AF effects

Cui et al. [2]

Nrf2 transfection enhances the efficacy of human amniotic mesenchymal stem cells to repair lung injury induced by lipopolysaccharide

Lung injury

hAMSCs

Preclinical

✓ Decreasing lung injury, lung fibrosis, and inflammation

AI and AF effects

Zhang et al .[3]

Conditioned medium from amniotic membrane-derived cells prevents lung fibrosis and preserves blood gas exchanges in bleomycin-injured mice-specificity of the effects and insights into possible mechanisms

Lung fibrosis

CM-hAMSCs

Preclinical

✓ Decreasing lung fibrosis and preserving the blood gas parameters

✓ Diminishing lung macrophage levels

IM, AI, and AF effect

Cargnoni et al. [4]

Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair

Lung fibrosis

hAECs

Preclinical

✓ Reducing inflammation and lung collagen.

AI and AF effects. Differentiation potential.

Moodley et al. [5]

Human amnion epithelial cells repair established lung injury

Lung injury

hAECs

Preclinical

✓ Normalizing lung tissue density, collagen content, and α-SMA production

✓ Diminishing pulmonary leucocytes and fibroblast activation in vitro

AI and AF effects

Vosdoganes et al. [6]

Title

Diseases

Cell type

Type of study

Outcome

Cell therapy

Authors

Human amnion epithelial cells mediate lung repair by directly modulating macrophage recruitment and polarization

Lung injury

hAECs

Preclinical

✓ Reducing macrophage infiltration.

✓ Modulating macrophage polarization

IM and AI effects

Tan et al. [7]

Human amnion epithelial cells prevent bleomycin-induced lung injury and preserve lung function

Lung injury

hAECs

Preclinical

✓ Decreasing gene expression of the proinflammatory cytokines

✓ Reducing pulmonary fibrosis and inflammatory cell infiltration

IM, AF and AI effects

Murphy et al. [8]

Human amnion epithelial cells modulate the inflammatory response to ventilation in preterm lambs

Preterm neonatal lung injury

hAECs

Preclinical

✓ Modulating the pulmonary inflammatory

✓ Reducing acute lung injury

IM effect

Melville et al. [9]

Human amnion cells reverse acute and chronic pulmonary damage in experimental neonatal lung injury

Neonatal lung injury

hAECs

Preclinical

✓ Improving lung architecture.

✓ Reducing macrophages, DC, NK, and pro-inflammatory cytokines.

IM and AI effects. Regenerative property.

Zhu et al. [10]

Amnion epithelial cell-derived exosomes restrict lung injury and enhance endogenous lung repair

Lung injury

EXO-hAECs

Preclinical

✓ Improving tissue-to-airspace ratio and reducing lung inflammation and fibrosis.

✓ Stimulating bronchioalveolar stem cell.

IM, AF and AI effects. Regenerative properties.

Tan et al. [11]

Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep

Fetal lung injury

hAECs

Preclinical

✓ Attenuating lung function and structure.

✓ Reducing proinflammatory cytokines.

AI effect

Vosdogans et al. [12]

First-in-human administration of allogeneic amnion cells in premature infants with bronchopulmonary dysplasia: a safety study

Broncho-

pulmonary dysplasia

hAECs

Clinical

phase I

✓ Administration was safe and tolerated.

✓ No adverse events. (Completed)

-

Lim et al. [13]

Human amnion cells for the prevention of bronchopulmonary dysplasia: a protocol for a phase I dose escalation study

Broncho-pulmonary dysplasia

hAECs

Clinical

phase I

✓ Safe and adverse events.

(Recruiting)

-

Baker et al. [14]

  1. CM-hAMSCs conditioned medium of human amniotic mesenchymal stromal cells, EXO-hAMSCs exosomes of human amniotic mesenchymal stromal cells, hAMSCs human amniotic mesenchymal stromal cells, hAECs human amniotic epithelial cells, EXO-hAECs exosomes of human amniotic epithelial cells, DC dendritic cells, NK natural killer cells, CT score computed tomography score
  2. Effects: AI anti-inflammatory, AF anti-fibrotic, IM immunomodulatory